Stockscreener 앱 받기
88.12
8.67%
7.03
시간 외 거래:
88.96
0.84
+0.95%
전일 마감가:
$81.09
열려 있는:
$81.3
하루 거래량:
1.39M
Relative Volume:
0.75
시가총액:
$5.54B
수익:
순이익/손실:
$-230.66M
주가수익비율:
-21.11
EPS:
-4.1742
순현금흐름:
$-148.12M
1주 성능:
-6.51%
1개월 성능:
+167.11%
6개월 성능:
+109.91%
1년 성능:
+492.20%
1일 변동 폭
$79.06
$88.50
1주일 범위
$79.06
$103.27
52주 변동 폭
$12.64
$104.00
Kodiak Sciences Inc Stock (KOD) Company Profile
명칭
Kodiak Sciences Inc
전화
650-281-0850
주소
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
88.12 | 5.54B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-24 | 재개 | Goldman | Neutral |
| 2026-05-11 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2025-11-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-25 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-09-22 | 개시 | Jefferies | Buy |
| 2025-08-14 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2023-12-11 | 재개 | Goldman | Sell |
| 2023-11-17 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-25 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-24 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-15 | 개시 | CapitalOne | Overweight |
| 2022-08-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-02-11 | 개시 | Goldman | Buy |
| 2022-02-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-03-12 | 개시 | Evercore ISI | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-02-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-11-30 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-11-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-03 | 개시 | Goldman | Buy |
| 2020-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-02-06 | 개시 | SunTrust | Buy |
| 2020-01-08 | 개시 | ROTH Capital | Buy |
| 2020-01-03 | 개시 | Jefferies | Buy |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-10-15 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-20 | 개시 | Chardan Capital Markets | Buy |
| 2018-10-29 | 개시 | Barclays | Overweight |
| 2018-10-29 | 개시 | BofA/Merrill | Buy |
| 2018-10-29 | 개시 | Morgan Stanley | Overweight |
모두보기
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance Singapore
Kodiak Sciences More Than Doubles on Eye Disease Trial Results - Barchart.com
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com South Africa
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Nigeria
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Canada
Kodiak Sciences(KOD.US) 10% Shareholder Buys US$156.99 Million in Common Stock - Moomoo
A stock acquisition changes beneficial ownership by more than 1% at Kodiak Sciences (KOD). - Stock Titan
Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media
In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD). - Stock Titan
Funds buy Kodiak Sciences (KOD) shares at average prices of about $79–$86. - Stock Titan
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Canada
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com South Africa
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Nigeria
Options at $2.49 a share are among those Kodiak Sciences (KOD) CEO exercised. - Stock Titan
Diluted net income available to common stockholders of Kodiak Sciences, Inc. – HAN:K27 - TradingView
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - Zacks Investment Research
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - Stocktwits
Kodiak Sciences Inc (NASDAQ: KOD) Share Price, KOD Stock News, KOD Share Price & Updates - Kalkine
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com Canada
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com India
Both treatments met a year-one vision goal in Kodiak Sciences (KOD)'s eye disease trial. - Stock Titan
Why Is Kodiak Sciences (NASDAQ:KOD) Suddenly a Must-Watch Healthcare Stocks Name? - Kalkine Media
Kodiak Sciences (Nasdaq:KOD)Stock Analysis - Simply Wall Street
Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are The 'Real Deal' (KOD) - Seeking Alpha
Kodiak Sciences to report phase 3 trial results Monday By Investing.com - Investing.com South Africa
What DAYBREAK Trial Results Could Mean For Kodiak Sciences Stock - simplywall.st
Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Kodiak Sciences (KOD) Pulls Back After A Strong Year, Is The Valuation Still Too Rich? - simplywall.st
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook - Investing.com India
After $435,870 sale, Gilead (NASDAQ: GILD) CFO still holds 164K shares - Stock Titan
3 Small-Cap Biotechs With Binary Catalysts on the Calendar - marketbeat.com
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance
Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews
Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan
Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
Kodiak Sciences Inc (KOD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kodiak Sciences Inc 주식 (KOD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Sep 29 '26 |
Buy |
85.05 |
33,726 |
2,868,255 |
20,191,214 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
83.58 |
418,323 |
34,963,077 |
19,515,907 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
72.57 |
807,840 |
58,625,708 |
19,121,134 |
| PERLROTH VICTOR | Chairman and CEO |
Sep 25 '26 |
Option Exercise |
4.20 |
1,280,524 |
5,381,943 |
3,676,062 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Sale |
34.10 |
30,000 |
1,023,009 |
211,930 |
| JOHN BORGESON | Officer |
Jun 04 '26 |
Proposed Sale |
33.87 |
30,000 |
1,016,100 |
0 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Option Exercise |
1.04 |
30,000 |
31,200 |
241,930 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 15 '26 |
Option Exercise |
1.04 |
28,614 |
29,759 |
211,930 |
| JOHN BORGESON | Officer |
Apr 02 '26 |
Proposed Sale |
42.81 |
30,000 |
1,284,300 |
0 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 02 '26 |
Sale |
39.92 |
30,000 |
1,197,488 |
183,316 |
0.03%
1.40%
자본화:
|
볼륨(24시간):